Deals in Depth: February 2011

01 Apr 2011

Executive Summary

Astellas added Phase III tivozanib to its pipeline in a $700mm deal with Aveo. Diagnostics and analytical testing companies fared well in M&A, including Danaher's $6.8 billion acquisition of Beckman Coulter. Biopharma financing jumped 7% to $1.9 billion, and device companies also raised more money than last month - $367 million vs. $189 million.

Already Registered? Sign in to continue reading.

New to In Vivo? Start a free trial today!

Table
View full table

Topics

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

IV003618

Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

IV003618

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Deals in Depth: February 2011

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Deals in Depth: February 2011

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert